HomeCompareJNCE vs YUM

JNCE vs YUM: Dividend Comparison 2026

JNCE yields 106.38% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNCE wins by $4.93M in total portfolio value
10 years
JNCE
JNCE
● Live price
106.38%
Share price
$1.88
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.04M
Annual income
$1,769,060.94
Full JNCE calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — JNCE vs YUM

📍 JNCE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJNCEYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JNCE + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JNCE pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JNCE
Annual income on $10K today (after 15% tax)
$9,042.55/yr
After 10yr DRIP, annual income (after tax)
$1,503,701.80/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, JNCE beats the other by $1,469,738.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JNCE + YUM for your $10,000?

JNCE: 50%YUM: 50%
100% YUM50/50100% JNCE
Portfolio after 10yr
$2.57M
Annual income
$904,509.13/yr
Blended yield
35.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

JNCE
Analyst Ratings
5
Buy
4
Hold
1
Sell
Consensus: Buy
Altman Z
0.6
Piotroski
3/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JNCE buys
0
YUM buys
0
No recent congressional trades found for JNCE or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJNCEYUM
Forward yield106.38%1.85%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$5.04M$107.0K
Annual income after 10y$1,769,060.94$39,957.33
Total dividends collected$4.53M$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: JNCE vs YUM ($10,000, DRIP)

YearJNCE PortfolioJNCE Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$21,338$10,638.30$10,980$280.44+$10.4KJNCE
2$44,047$21,215.25$12,185$435.72+$31.9KJNCE
3$88,059$40,928.25$13,722$684.14+$74.3KJNCE
4$170,693$76,470.42$15,773$1,090.14+$154.9KJNCE
5$321,175$138,533.11$18,650$1,773.02+$302.5KJNCE
6$587,267$243,609.90$22,921$2,966.37+$564.3KJNCE
7$1,044,675$416,298.80$29,685$5,158.69+$1.01MJNCE
8$1,809,898$692,096.64$41,216$9,453.02+$1.77MJNCE
9$3,057,206$1,120,614.24$62,672$18,571.31+$2.99MJNCE
10$5,040,271$1,769,060.94$107,016$39,957.33+$4.93MJNCE

JNCE vs YUM: Complete Analysis 2026

JNCEStock

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Full JNCE Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this JNCE vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JNCE vs SCHDJNCE vs JEPIJNCE vs OJNCE vs KOJNCE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.